featured
Abemaciclib Plus Tamoxifen in Patients With Endocrine-Refractory HR+/HER2– Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer
Breast Cancer Res Treat 2022 Jul 12;[EPub Ahead of Print], E Hamilton, J Cortes, O Ozyilkan, SC Chen, K Petrakova, A Manikhas, G Jerusalem, R Hegg, J Huober, W Zhang, Y Chen, M MartinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.